SAGe Safety Signal Assessment Assistant

SAGe Safety Signal Assessment Assistant

SAGe Safety Signal Assessment Assistant

What Is This Assistant?

This tool guides you through a structured, reproducible safety signal assessment using the SAGe (Signal Assessment Guide) methodology, developed at AstraZeneca. It is meant for pharmacovigilance professionals and safety teams evaluating causality for signals from medicinal products.

How To Use: Overview

  • Select the most robust level of evidence available in each category: Aggregate Safety Data, Plausibility Data, and Case-Level Data.
  • Write concise summaries for each type of data to record key logic, findings, and context.
  • When ready, click Generate Signal Strength Summary for an integrated visual and textual output to inform meetings and recommendations.

Step 1: Prepare Your Evidence

Gather and review all relevant data for the potential safety signal.
Assess what data you have in each of these three broad types before starting:
  • Aggregate Safety Data: Trials, meta-analyses, databases, surveillance tools.
  • Plausibility Data: Scientific/mechanistic rationale, class effect, regulatory precedent.
  • Case-Level Data: Individual case reports, rechallenge cases, antidote responses.
Tip: Not every assessment will have strong evidence in all three categories. Work with what is available and document N/A where there's no robust information.

Step 2: Rate Evidence Levels

Assign the highest grade of evidence available in each category. Grades range from:
  • Level A: Unambiguous, definitive data.
  • Level B: Robust or probable, but not unequivocal.
  • Level C: Possible, but missing/conflicted/confounded.
  • Level D: Weak, ambiguous or only speculative support.
  • N/A: No qualifying data in this category.
See descriptions below each category for more detailed guidance.

Aggregate Safety Data

Includes: RCTs, meta-analyses, cohort studies, safety database analyses, epidemiological controls.
Level A: Large, dedicated clinical trials or systematic reviews showing clear statistical outcome.
Level B: Robust interventional trials with statistically significant risk; compelling reviews; consistent findings in strong cohort studies.
Level C: Trials with imbalances or dose relationships, notable but not definitive findings.
Level D: Suggestive results, uncontrolled studies, high frequency in surveys or reporting systems (FAERS, VigiBase).

Plausibility Data

Includes: Mechanistic rationale (biology/pharmacology), established class effects, regulatory precedent.
Level A: Definitive mechanistic causation confirmed by robust science and label consensus.
Level B: Probable mechanism, class effect widely recognized by health agencies.
Level C: Possible but conflicted/scant mechanism, limited label support.
Level D: Theoretical, speculative, or solely expert opinion (no supporting data).

Case-Level Data

Includes: Analysis of designated medical events, rechallenge, antidote responses, overdose reports.
Level A: Compelling case series (unconfounded DMEs), unequivocal rechallenge or antidote reversal.
Level B: Suggestive but partially confounded cases, single robust DME, or antidote effect in convincing case.
Level C: Confounded but suggestive data, positive findings in otherwise flawed reports.
Level D: Highly confounded cases, speculative relationship, possible but not convincing outcome.

Step 3: Generate and Interpret the Summary

After completing all fields:
  • Click Generate Signal Strength Summary below to view your final output.
  • Review integrated evidence grades and rationale. The output can be used to support safety meetings, documentation, and regulatory reporting.
  • Remember: This tool supplements, not replaces, medical and scientific judgement.